文摘
摘要目的:评估是否持续时间和/或发病年龄REM睡眠行为障碍(RBD)的孤立RBD (iRBD)患者影响的结果演变成一个公开的synucleinopathy。
背景:iRBD病人高危,开发一个公开synucleinopathy(即。,dementia with Lewy bodies (DLB) or Parkinson’s disease (PD)] and RBD often precedes years or decades before diagnosis of DLB or PD.
设计/方法:参与者与polysomnography-confirmed iRBD一直遵循前瞻性> 4年了。
结果:15个参与者(45%)开发下文(phenoconverters)和18名参与者(55%)仍然iRBD iRBD(稳定)。后续年phenoconverters稳定iRBD之间没有差别(6.2±2.5 vs 6.3±1.2年;p = 0.86)。时间从基线访下文诊断为4.0±1.9年,时间从RBD出现下文诊断为10.9±5.4年。在基线,phenoconverters年龄(69.4±6.8 vs 63.7±5.6岁;p = 0.013), MMSE得分较低(27.3±1.5 vs 28.9±1.3;p = 0.002),有更多的消极DaTQUANT壳z得分在123 i-fp-cit SPECT (−1.71±1.42 vs−0.28±1.21;p = 0.004)。性别(男;87%和78%; p=0.51), education years (16.7 ± 2.5 vs 17.4 ± 2.4 years; p=0.38),APOE4承运人(27% vs 35%;p = 0.60),第三部分UPDRS评分(3.2±3.2 vs 1.5±2.1;p = 0.073),两组之间没有差别。Phenoconverters提出RBD持续时间短(6.9±4.4 vs 16.3±12.3年;p = 0.008)及以上RBD发作(62.5±8.3 vs 47.3±14.9岁;p = 0.001)。
结论:这些发现表明,iRBD短持续时间和老出现RBD患者增加发展成一个公开synucleinopathy的可能性。
披露:Miyagawa博士没有披露。斯科特Przybelski没有披露。Hoon-Ki分钟没有披露。列侬乔丹没有披露。弗农太太没有披露。盖Lesnick已收到个人赔偿作为梅奥诊所的一名雇员。迈克博士没有披露。圣路易博士已经收到相关出版物的出版版税卫生保健。圣路易博士已经收到相关出版物的出版版税卫生保健。Silber博士已经收到相关出版物的出版版税卫生保健。 Dr. Silber has received personal compensation in the range of $500-$4,999 for serving as a Topic writer with UpToDate. Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. The institution of Dr. Graff-Radford has received research support from NIH. Dr. Jones has nothing to disclose. Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nestle. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech, Inc.. Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche, Inc.. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. The institution of Walter Kremers has received research support from Biogen. Ms. Forsberg has nothing to disclose. The institution of Dr. Fields has received research support from National Institutes of Health. The institution of Dr. Fields has received research support from Patient-Centered Outcomes Research Institute. Ms. Ferman has nothing to disclose. Dr. Botha has received research support from NIH. Dr. Ramanan has nothing to disclose. Ms. Allen has nothing to disclose. The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF. Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals. Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from GE Healthcare. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
